ClinicalTrials.gg
TerminatedNCT03645928Updated May 15, 2026

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

A Phase 2 interventional study of Lifileucel and LN-145 in Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck and Non-small Cell Lung Cancer, sponsored by Iovance Biotherapeutics, Inc.. Terminated at 34 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing lifileucel in Melanoma — 4 open to participants now, 7 under way, 1 of them phase 3. lifileucel · Melanoma.

Enrollment
2nd of 13
225 · median 10
Started
2019
the only one that year
Phase 2
4 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
4 of 13
Iovance Biotherapeutics, Inc.

Among the 13 studies testing lifileucel in Melanoma, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 4 in phase 2, and was the 2nd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 13 studies testing lifileucel in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lifileucel

lifileucel: first FDA approval 2024 (AMTAGVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing lifileucel in Melanoma, or all of them as a file.
02

Study summary

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL [LN-144/LN-145 (lifileucel) and LN-145-S1] as a single agent therapy.

Read the detailed description

TIL [LN-144/LN-145 (lifileucel) and LN-145-S1] is an adoptive cell transfer therapy that utilizes an autologous TIL for the treatment of patients with unresectable or metastatic melanoma; advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck; and locally advanced or metastatic non-small-cell lung cancer. The adoptive cell transfer therapy used in this study involves patients receiving a nonmyeloablative lymphodepletion (NMA-LD) regimen, followed by autologous TIL infusion , then aldesleukin administration. Patients in Cohorts 1A, 1D, 2A, 3A, 3C, 3D, and 3E will receive TIL plus immune checkpoint inhibitors. Patients in Cohorts 1B, 1C, and 3B will receive autologous TIL as a single therapy.

03

Conditions studied

  • Metastatic Melanoma
  • Squamous Cell Carcinoma of the Head and Neck
  • Non-small Cell Lung Cancer

Keywords

  • LN-144
  • LN-145
  • Cell Therapy
  • Autologous Adoptive Cell Transfer
  • Autologous Adoptive Cell Therapy
  • Cellular Immuno-therapy
  • Tumor Infiltrating Lymphocytes
  • TIL
  • IL-2
  • Multiple Tumor Type
  • Lifileucel
  • Pembrolizumab
  • LN-145-S1
  • Ipilimumab
  • Nivolumab
  • ICI
  • Immune Checkpoint Inhibitor
  • Aldesleukin
  • Non-small cell lung cancer
  • Melanoma
  • NSCLC
  • Nivolumab-relatlimab
  • Head-and-neck squamous cell carcinoma
  • HNSCC
  • Platinum doublet chemotherapy agents
  • Cisplatin
  • Carboplatin
  • Paclitaxel
  • Nab-Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a confirmed diagnosis of of their receptive [RL7.1]histologies: unresectable or melanoma Stage IIIC to IV (Cohorts 1A,1B and 1C), advanced, recurrent or metastatic HNSCC (Cohort 2A), or Stage III or Stage IV non-small cell lung cancer (Cohorts 3A, 3B, and 3C). Stage IV NSCLC with no actionable mutations (EGFR, ALK, ROS1) with effective targeted therapy (Cohorts 3D and 3E).
  • Cohorts 1A, 1D, 2A, 3A, 3D and 3E: If previously treated, patients must have progressed on or after most recent therapy and must not have received ICIs as part of one of the counted . Patients must have radiologically documented disease progression while receiving or after the completion of the most recent prior treatment. Patients may have received up to 3 prior systemic anticancer therapies (except for Cohort 3A, where patients whose tumors harbor actionable mutations may have received up to 4 prior systemic therapies). Patients in Cohort 1D may have had no prior therapy for advanced disease. Patients in Cohorts 3D and 3E may have had no prior systemic therapy for Stage IV disease.
  • Cohorts 1B, 1C, 3B, and 3C: Unresectable or metastatic melanoma patients in Cohorts 1B or 1C must have previously received systemic therapy with a blocking antibody. NSCLC patients in Cohort 3B must have previously received systemic therapy with any ICI (except for those patients with known oncogene driver mutations that are sensitive to targeted therapies) as part of 1 - 3 prior lines of therapy. NSCLC patients in Cohort 3C must have previously received 1 line of ICI monotherapy. No other systemic therapy for metastatic disease is allowed. Prior chemoradiation and/or chemotherapy in the and/or neoadjuvant settings are allowed.
  • Must have at least 1 resectable lesion
  • Must have remaining as defined by 1.1 following tumor resection
  • Must be ≥ 18 years at the time of consent for Cohorts 1A, 1C, 1D, 2A, 3A, 3B, 3C, 3D and 3E. Patients must be ≥ 12 years at the time of consent for Cohort 1B. Enrollment of patients > 70 years of age may be allowed after consultation with the Medical Monitor.
  • Must have an (ECOG) performance status of 0 or 1, and an estimated of ≥ 6 months.
  • Patients of or those with partners of childbearing potential must be willing to practice an approved method of during treatment and for 12 months after their last dose of aldesleukin, 4 months after their last dose of pembrolizumab, 5 months after their last dose of ipilimumab or nivolumab, or nivolumab-relatlimab; 6 months after the last dose of carboplatin; 14 months after the last dose of cisplatin; and 6 months after the last dose of pemetrexed, paclitaxel, or nab-paclitaxel, whichever occurs later.

Exclusion criteria

Exclusion Criteria

  • Patients with melanoma of uveal/ocular origin.
  • Patients who have a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years. Patients being retreated with TIL, as part of this study are not excluded.
  • Patients who have symptomatic, untreated or history of .
  • Patients who are on systemic therapy > 10 mg/day of prednisone or other steroid equivalent. Patients receiving steroids as replacement therapy for adrenocortical insufficiency at ≤ 10 mg/day of prednisone or other steroid equivalent may be eligible.
  • Patients who are pregnant or breastfeeding.
  • Patients who have an active medical illness(es), which in the opinion of the Investigator, would pose increased risks for study participation
  • Cohort 1A, 1D, 2A, 3A, 3C, 3D and 3E patients may not have a medical history of disorders (including pneumonitis) requiring treatment or active management.
  • Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
  • Patients who have any form of primary immunodeficiency
  • Patients with a history of to any component of the study drugs to be administered in the pertinent cohort(s).
  • Patients who have a (LVEF) \< 45% or who are Class II or higher. A cardiac stress test demonstrating any irreversible wall movement abnormality in any patients ≥60 years of age or in patients who have a history of ischemic heart disease, cardiac chest pain, or atrial and/or ventricular arrhythmias.
  • Patients with respiratory dysfunction or history of smoking are excluded if not meeting either of (FEV1)/forced vital capacity (FVC) > 0.7 or FEV1 > 50%.
  • Patients who have had another primary within the previous 3 years
  • Participation in another interventional clinical study within 21 days prior to the initiation of treatment.
  • Patients in Cohorts 1D, 3D, or 3E who previously received adjuvant or ICI(s) for non- disease and had an immune-related AE(s) requiring systemic steroid treatment or discontinuation of therapy.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Cohort 1A

    Lifileucel (LN-144) regimen in combination with pembrolizumab in patients with Stage IIIC to IV unresectable or metastatic melanoma with ≤ 3 prior lines of systemic therapy, excluding immune checkpoint inhibitors (ICI).

    Biological: Lifileucel · Drug: Pembrolizumab

  • Experimental
    Cohort 1B

    LN-145-S1 regimen in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor with or without a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.

    Biological: LN-145-S1

  • Experimental
    Cohort 1C

    Lifileucel (LN-144 Generation 3 \[Gen 3\]) regimen in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.

    Biological: Lifileucel

  • Experimental
    Cohort 2A

    Lifileucel (LN-145) regimen in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding ICIs.

    Biological: Lifileucel · Biological: LN-145 · Drug: Pembrolizumab

  • Experimental
    Cohort 3A

    Lifileucel (LN-145) regimen in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III or Stage IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding ICIs, or ≤ 4 lines if 2 or more of the lines are tyrosine kinase inhibitor (TKI) therapy for those with tumors that harbored actionable mutations (eg, EGFR, ALK, ROS).

    Biological: Lifileucel · Biological: LN-145 · Drug: Pembrolizumab

  • Experimental
    Cohort 3B

    Lifileucel (LN-145) regimen ent in patients with Stage III or Stage IV NSCLC, who have previously received 1-3 lines of prior systemic therapy. Patients with known oncogene drivers (eg, EGFR, ALK, ROS) who have mutations that are sensitive to targeted therapies are not required to have received prior systemic therapy with ICIs.

    Biological: Lifileucel · Biological: LN-145

  • Experimental
    Cohort 3C

    Lifileucel (LN-145) regimen in combination with ipilimumab and nivolumab in patients with Stage III or Stage IV NSCLC who have previously received 1 line of ICI monotherapy. No other systemic therapy for metastatic disease is allowed. Prior chemoradiation and/or chemotherapy in the adjuvant and/or neo-adjuvant settings are allowed.

    Biological: Lifileucel · Biological: LN-145 · Drug: Ipilimumab · Drug: Nivolumab

  • Experimental
    Cohort 3D

    Lifileucel regimen in combination with pembrolizumab with or without pemetrexed, given after tumor resection then 4 cycles of frontline platinum doublet chemotherapy plus pembrolizumab, in patients with Stage IV NSCLC without EGFR, ALK, or ROS1 driver mutations, who have had no prior therapy for advanced disease.

    Biological: Lifileucel · Biological: LN-145 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: Pemetrexed

  • Experimental
    Cohort 3E

    Lifileucel regimen in combination with pembrolizumab with or without pemetrexed, given after 4 cycles of frontline platinum doublet chemotherapy plus pembrolizumab with tumor resection between any 2 cycles, in patients with Stage IV NSCLC without EGFR, ALK, or ROS1 driver mutations.

    Biological: Lifileucel · Biological: LN-145 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: Pemetrexed

  • Experimental
    Cohort 1D

    Lifileucel (LN-144) regimen in combination with nivolumab-relatlimab in patients with Stage IIIC to IV unresectable or metastatic (advanced) melanoma who have had no prior therapy for advanced disease.

    Biological: Lifileucel · Drug: Nivolumab-relatlimab

Interventions

  • BiologicalLifileucel

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor-infiltrating lymphocytes (TIL). After NMA-LD, patients receive lifileucel, followed by aldesleukin administration. Lifileucel will be administered to patients once (on Day 0) during the study.

    Also known as: LN-144, TIL, autologous tumor-infiltrating lymphocytes

  • BiologicalLN-145

    Drug pages: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.

    Also known as: TIL, autologous tumor infiltrating lymphocytes

  • Humanized antibody. Pembrolizumab will be administered after tumor resection and will continue every 3 weeks or every 6 weeks for up to 2 years.

    Also known as: Keytruda

  • BiologicalLN-145-S1

    A tumor sample is resected from each patient and cultured ex vivo to expand the population of TIL, then TIL with high levels of PD-1 surface expression are selected. After NMA-LD, patients receive their autologous PD-1-selected TIL (LN-145-S1), followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.

    Also known as: TIL, autologous tumor-infiltrating lymphocytes, PD-1-selected TIL

  • Monoclonal antibody Ipilimumab will be administered as a single dose prior to tumor resection.

    Also known as: Yervoy

  • Monoclonal antibody. Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to starting NMA-LD and will continue every 4 weeks for up to 2 years.

    Also known as: Opdivo

  • DrugNivolumab-relatlimab

    Monoclonal antibody (nivolumab) and monoclonal antibody (relatlimab). Nivolumab-relatlimab will be administered after tumor resection and will continue every 4 weeks for up to 2 years.

    Also known as: Opdualag

  • Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Nab-Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

  • Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if applicable.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    To evaluate the efficacy of autologous TIL in combination with ICIs in metastatic melanoma, HNSCC, and NSCLC patients and as a single therapy in metastatic melanoma and NSCLC patients as determined by objective response rate (ORR) using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by Investigator

    Time frame: Up to 60 months

  2. Safety Profile Measured by Grade ≥3 TEAEs

    To characterize the safety profile of autologous TIL in combination with ICIs in metastatic melanoma, HNSCC, and NSCLC patients and as a single therapy in metastatic melanoma and NSCLC patients as measured by the incidence of Grade ≥ 3 treatment-emergent adverse events (TEAEs)

    Time frame: Up to 60 months

  3. Percentage of patients for whom lifileucel is successfully manufactured and meets release specification

    To evaluate the feasibility of producing lifileucel using tumor samples obtained before (Cohort 3D) or during (Cohort 3E) frontline platinum doublet chemotherapy and pembrolizumab in patients with Stage IV NSCLC

    Time frame: Up to 60 months

Secondary outcomes

  1. Complete Response Rate

    To evaluate efficacy using Complete Response (CR) rate per RECIST 1.1, as assessed by the Investigator

    Time frame: Up to 60 months

  2. Duration of Response

    To evaluate efficacy using Duration of Response (DOR) per RECIST 1.1, as assessed by the Investigator

    Time frame: Up to 60 months

  3. Disease Control Rate

    To evaluate efficacy using Disease Control Rate (DCR) per RECIST 1.1, as assessed by the Investigator

    Time frame: Up to 60 months

  4. Progression-Free Survival

    To evaluate efficacy using Progression-Free Survival (PFS) per RECIST 1.1, as assessed by the Investigator

    Time frame: Up to 60 months

  5. Overall Survival

    To evaluate efficacy using Overall Survival (OS)

    Time frame: Up to 60 months

07

Study locations

34 sites
  • University of California, San Diego
    La Jolla, California 92093, United States
  • University of Southern California
    Los Angeles, California 90007, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • University of Colorado
    Denver, Colorado 80045, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • Orlando Health Cancer Institute
    Orlando, Florida 32610, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Louisville
    Louisville, Kentucky 40292, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • MD Anderson at Cooper
    Camden, New Jersey 08103, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Ohio State University
    Columbus, Ohio 43201, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2C1, Canada
  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck
    Lübeck, Schleswig-Holstein 23538, Germany
  • Laiko General Hospital of Athens
    Athens, Attica 11527, Greece
  • Attikon University General Hospital
    Athens, Attica 12461, Greece
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Regional Universitario de Malaga - Hospital General
    Málaga, Málaga 29016, Spain
  • ICO l'Hospitalet - Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Universitaetsspital Bern
    Bern, 3010, Switzerland
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, 1011, Switzerland
  • Guy's Hospital
    London, England SE19RT, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, England SW3 6JJ, United Kingdom
08

References and documents

Publications

  • Hensel J, Metts J, Gupta A, Ladle BH, Pilon-Thomas S, Mullinax J. Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy. Cancer J. 2022 Jul-Aug 01;28(4):322-327. doi: 10.1097/PPO.0000000000000603. PubMed 35880942 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Feb 2026, 81 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2018
First posted
Aug 24, 2018
StartActual
May 7, 2019
Primary completionActual
Feb 20, 2026
CompletionActual
Feb 20, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03645928
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 24, 2018
Start date
May 7, 2019
Primary completion
Feb 20, 2026
Completion
Feb 20, 2026
Last update
May 15, 2026

Study contacts

Iovance Biotherapeutics Medical Monitor
study director · Iovance Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145

Start the discussion